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Abstract- Retinoblastoma is the most common intraocular tumor in children resulting from genetic 
alterations and transformation of mature retinal cells. The objective of this study was to investigate the effects 
of SD-208, TGF-β-RI kinase inhibitor, on the expression of some miRNAs including a miR-17/92 cluster in 
retinoblastoma cells. Prior to initiate this work, the cell proliferation was studied by Methyl Thiazolyl 
Tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Then, the expression patterns of four 
miRNAs (18a, 20a, 22, and 34a) were investigated in the treated SD-208 (0.0, 1, 2 and 3 µM) and untreated 
Y-79 cells. A remarkable inhibition of the cell proliferation was found in Y-79 cells treated with SD-208 
versus untreated cells. Also, the expression changes were observed in miRNAs 18a, 20a, 22 and 34a in 
response to SD-208 treatment (P<0.05). The findings of the present study suggest that the anti-cancer effect 
of SD-208 may be exerted due to the regulation of specific miRNAs, at least in this particular retinoblastoma 
cell line. To the best of the researchers’ knowledge, this is the first report demonstrating that the SD-208 
could alter the expression of tumor suppressive miRNAs as well as oncomiRs in vitro. In conclusion, the 
present data suggest that SD-208 could be an alternative agent in retinoblastoma treatment. 
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(6):352-358. 
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Introduction 
 
Retinoblastoma (Rb), the most common pediatric 
cancer of the eye, exists in sporadic and heritable forms 
(1). Two kinds of this cancer, bilateral (15% inheritable) 
and unilateral (85% non-heritable) have been reported. 
This malignancy occurs as part of a familial cancer 
syndrome; however, the main ratio of retinoblastoma 
arises with no preceding family history (2). 
Retinoblastoma is first cancer confirmed to have a 
genetic origin (2,3). Although genetic changes in Rb 
gene have been frequently reported in retinoblastoma, 
the genetic alteration in other biomolecules and  genes 
such as MYCN oncogene appears to be important in its 
pathogenesis (4-8). Studies have shown that 
inappropriate expression or loss of RB function is 
associated with other human cancers (9-13).  
Today, it is well known that numerous biomolecules 
such as micro RNAs (miRNAs) and long non-coding 
RNAs (lncRNAs) are implicated in the regulation of 
various human cancer genes (14-19). For instance, these 
molecules play a vital role in tumor suppressor networks 
such as RB gene (20). The expression profile and 
biological significance of miRNAs depend on the target 
genes and kind of malignancy (tumor 
microenvironment). Many researchers determined that a 
specific group of miRNAs is highly expressed in 
multiple tumor types and turn on some oncogenes while 
overexpression of another group leads to the activation 
of some tumor suppressor genes. It is quite 
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understandable, therefore, that these molecules could be 
used as biomarkers and targets for the cancer diagnosis 
and therapy, respectively.  
In spite of the fact that the survival rate of 
retinoblastoma is about 98%, chemotherapeutic 
resistance and various side effects of current therapies 
are considered the main challenges for this disease. 
Studies have shown that the pretreatment evaluation of 
retinoblastoma cases is individualized and directed by 
the chosen mode of therapy. The present study, for the 
first time, investigated the effect of a TGβRI kinase 
inhibitor, SD-208, on the regulation of four miRNAs 
18a, 20a, 22 and 34a in retinoblastoma 
 
Materials and Methods 
 
Cell culture 
The human retinoblastoma Y-79 cell line was 
obtained from National Cell Bank of Iran (NCBI) 
affiliated to Pasteur Institute (Tehran, Iran). The cells 
were grown in suspension at a concentration of 105-106 
cells/ml in RPMI-1640 medium (Gibco; Germany) 
containing 10% fetal bovine serum (FBS) (Gibco; 
Germany), 2 mM L-glutamine, 1 mM sodium pyruvate, 
and antibiotics (100 U/ml of penicillin and 100 μg/ml of 
streptomycin). Cell culture condition designed at 37°C 
in a humidified atmosphere of 5% CO2-95% air. 
 
SD-208 treatment 
The treatment of cells with SD-208 (Sigma-Aldrich, 
Belgium) was conducted as previously described (21). 
Briefly, SD-208 was dissolved in dimethyl sulfoxide 
(DMSO) with a concentration of 20 µM and stored at -
20°C. The Y-79 cells in each experiment were treated 
using a different range of SD-208 concentrations (as 
explain in the below sections). 
 
MTT assay 
The cytotoxicity effect of SD-208 was measured by 
the MTT assay as previously described (21,22). Briefly, 
Y-79 cells were seeded in 96-well flat-bottom 
microtitration plates (SPL Life Sciences; South Korea) 
at a density of 4×104 cells/well (200 μl media/well). 
After reaching to ~85% confluency, the cells were 
treated with various concentrations of SD-208 (0.0, 1, 2, 
3 µM). In all in vitro experiments, control cells were 
incubated with dimethyl sulfoxide (DMSO) alone (with 
a final concentration 0.2%).  
 
BrdU assay 
The BrdU assay was performed using BrdU ELISA 
kit as previously described (21). Briefly, the Y-79 cells 
were seeded in 96-well flat-bottom microtitration plates 
at a density of 4×104 cells/well (100 μl media/well). 
Then, the cells were treated with SD-208 (0.0, 1, 2, 3 
µM) and the cell apoptosis calculated as previously 
described (21). 
 
Total RNA extraction  
The isolation of total RNA from cells with a cell 
density of 80% confluent was conducted using Trizol® 
total RNA isolation reagent (Gibco BRL, Life 
Technologies, Gaithersburg, MD, USA) according to the 
manufacturer’s instructions. To remove any genomic 
contamination, the total RNA was treated with RNase-
free DNase I and stored at -70° C for further tests.  
 
miRNA expression analysis by Real-time q-PCR 
Four miRNAs (including miR-18a, 20a, 22, 34a) 
genes involving in retinoblastoma were selected from 
the Sanger Center miRNA Registry at 
http://www.sanger.ac.uk/Software/Rfam/mirna/index.sht
ml.  
The microRNAs expression was analyzed by real-
time quantitative polymerase chain reactions (qPCR) 
using the SYBR Green method by the specific primers 
for mature forms of aforementioned micro RNAs as per 
the manufacturer’s instructions (Parsgenom, Iran). The 
real-time q-PCR carried out by poly (A) tailing method 
relying on polyadenylation, followed by cDNA 
synthesis using a universal oligo(dT) primer. RNU6B 
was used as an endogenous (internal) control, and the 
data were normalized to the expression level of this 
housekeeping gene.  
Our protocol consisted of two steps: reverse 
transcription (RT) and real-time PCR. First, RNA was 
transcripted to complementary DNA (cDNA) using the 
poly-adenylation procedure. Briefly, a 20 µl reaction 
including 2 μg total RNA, 2 µl of 10X reaction buffer, 2 
µl of 10 mM ATP and 1 unit of Poly (A) polymerase 
was incubated at 38 °C for 30 min, followed by enzyme 
inactivation at 65 °C for 3 min. After polyadenylation, 
the cDNA was synthesized using 2 μg of polyadenylated 
RNA (RNA poly A tail) and miR-cDNA Syn specific 
primers in a reverse transcription reaction. This reaction 
was performed in a volume of 10 μl containing 1 µl of 
the polyadenylation reaction product, 1 µl of 0.5 mM 
universal RT primer, 1 µl of 10 mMdNTP, 0.5 µl of RT 
enzyme in. The reaction was incubated at 42 °C for 60 
min and then terminated by heating at 85 °C for 5 min.  
Diluted cDNAs then were amplified in a 20μl 
reaction containing SYBER Green Mastermix, forward 
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and reverse miR-specific primers (each 1 μl) and DEPC-
treated distilled water by 35 cycles of PCR amplification 
under the following conditions: denaturing at 95 °C for 1 
min, annealing at 60 °C for 1 min, and extension at 72 
°C for 1 min. Real-time PCR was performed on a Bio-
Rad CFX96 Real-Time PCR System.  
All the reactions were performed in triplicate. 
Specificity of primers was verified by observing a single 
peak dissociation curve for each run. The threshold 
cycle (CT) is defined as the fractional cycle number at 
which the fluorescence passes the fixed threshold. CT 
values were converted into total copy numbers using a 
standard curve. The absence of contamination was 
verified using non-template controls. 
 
Statistical analysis  
Statistical analysis for multiple comparisons of 
differences between treatment groups was performed 
with SPSS software. The standard error of means was 
computed, and analysis of variance (ANOVA, Tukey 
post tests) completed via GraphPad Prism 5.0 software. 
Gene expression analysis was performed by 2-∆∆ct 
method via GraphPad Prism 5.0 software. P˂0.05 were 
considered as statistically significant. 
 
Results 
 
SD-208 decreases proliferation of and induces 
apoptosis in Y-79 cells 
    To determine the inhibitory effect of SD-208on cell 
proliferation in Y-79 cells, the cell growth was analyzed 
by performing MTT assay with various conditions. The 
data resulted from the present study clearly showed that 
SD-208treatment significantly reduces the viability of 
Y-79 cells in a dose- and time-dependent manner. 
Figure1 shows the cell response to different drug 
concentrations (0.0, 1, 2, 3 µM) for a time course of 24, 
48, and 72 h. The results of cell function assays revealed 
a significant change in the cell viability in the treated 
versus untreated Y-79 cells (P<0.05), especially at 48h 
and 72h. 
Moreover, to examine whether SD-208can promote 
apoptosis in Y-79 cells, we analyzed apoptotic index 
using a BrdU experiment in the SD-208treated cells 
compared to controls (Figure 2). The apoptotic findings 
revealed a significant change in cell death in the treated 
versus control cells (P<0.05) at 48h and 72h. 
The obtained results show that the cytotoxicity and 
apoptosis effects of SD-208on retinoblastoma cell line 
are time and dose-dependent. Besides, its apoptotic 
effect like its toxicity seems to follow a time and dose-
dependent manner. 
 
 
Figure  1. Effect of SD-208 on the Y-79 cell viability. Y-79 cells were 
treated by 0.0, 1, 2 and 3 µM for different time courses. The cell 
toxicity was examined by MTT assay and data was reported as the 
percentage change in comparison with the controls. Comparison of the 
cell viability of Y-79 cells in different concentrations of SD-208 to 
controls was analyzed by one-way ANOVA test. Results were 
expressed as mean ±SEM from three independent experiments. P<0.05 
was considered as statistically significant 
 
 
Figure  2. Impact of SD-208 on the Y-79 cell proliferation. The Y-79 
cells were treated by 0.0, 1, 2 and 3 µM for different time courses. Cell 
apoptosis was examined by BrdU assay and analysis of one-way 
ANOVA was used to compare the cell apoptosis. Results were 
expressed as mean ±SEM from three independent experiments. P<0.05 
was considered as statistically significant 
 
SD-208regulates miRNA expression in 
retinoblastoma 
    To study the ability of the SD-208as a potential 
anticancer agent via changing oncogene/tumor 
suppressor miRNAs, the researchers partially evaluated 
its effects on some miRNA expression. As Figure 3 
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shows, SD-208could significantly upregulate miR-18a, 
22a, and 34a (P<0.05) while downregulating miR-20a 
(P<0.05) expression in retinoblastoma cells.  
 
Figure  3. Effect of SD-208 on miRNA expression. Evaluation of the 
ffects of SD-208 on miRNA expression was completed by Real-time 
q-PCR. SD-208 could significantly upregulate miR-18a, 22a, and 34a 
(P<0.05) while downregulating miR-20a (P<0.05) expression 
 
Discussion 
 
It is well established that TGFβ signaling pathway 
plays a critical role in the normal and abnormal cellular 
processes. In this study, we focused on the involvement 
of miRNAs in the anticancerous effect of SD-208. We 
found that the kinase inhibitor, SD-208, was able to 
inhibit TGF-β-evoked proliferation in retinoblastoma via 
regulation of cancer-related miRNAs. A few reports 
suggested that SD-208 could not be an effective 
chemotherapeutic agent in at least some human cancers 
(21,23). Although in a study it was shown that SD-208 
could decrease the tumor angiogenesis in athymic nude 
mice, it was not able to inhibit mammary tumor growth 
and metastasis. Most recently, Akbari et al., reported no 
significant reduction in cell proliferation and 
angiogenesis in human colon adenocarcinoma cells 
treated with SD-208 (21). 
In contrast, to work described above, accumulated 
data have demonstrated the potential anti-cancer 
activities of SD-208 (24-26) in distinct malignancies 
such as pancreatic (27,28), glioma (25) and melanoma 
(24). Mohammad KS defined SD-208 as promising 
novel agents for the treatment of human malignant 
glioma and other conditions associated with pathological 
TGFβ activity. Also, Uhl M demonstrated that the 
targeting of TGF-β signaling pathway by SD-208 may 
prevent the development of melanoma bone metastases. 
However, these reports do not address exactly how SD-
208 regulates miRNA expression and the genes which 
are implicated in the cancer therapy. 
Our study identified that miR18a to be modulated by 
SD-208. The miR18a overexpression seems to be an 
important factor in cancer treatment. Krutilina et al. 
reported that miR18a expression suppressed distant 
metastasis via the hypoxia-inducible factor 1-alpha 
pathway (29). Interestingly, it is well known that 
neglected or untreated retinoblastoma cases can 
demonstrate extraocular spread, primarily through the 
optic nerve (30,31). Based on these observations, it 
might be possible that the overexpression of miR18a 
could be implicated in repressing the metastatic behavior 
of intraocular retinoblastoma. In addition, miR-34 and 
miR-22 in our study following real time RT-PCR 
validation demonstrated a significant upregulation in 
treated Y-79 with SD-208 cells as compared to the 
controls. The miR-34 family has three members, miR-34 
a,b,c. It has been thought that miR-34a is an important 
regulator of tumor suppression. This molecule controls 
different aspects of cell cycle processes such as 
differentiation and apoptosis; Its differential expression 
has been detected in different cancer such as breast, 
melanoma, pancreatic, and prostate cancer cell lines 
(32). However, the exact molecular mechanisms by 
which it acts as an anti-oncogenic activity is not well 
known. Various studies demonstrated that miR-34a is 
regulated by diverse approaches such as p53-dependent 
(33-35) and p53-independent mechanisms (36-38). 
TGFβ signaling pathway as a molecular target for the 
miR-34a could also be another proposed model of 
function. More recently, a study suggested the capability 
of miR-34a to suppress epithelial-mesenchymal 
transition (EMT) in human cancer through TGFβ 
signaling pathway (39). In addition, a cross talk between 
miR-34a, as a complex network interaction could 
interpret the miR-34a-mediated apoptosis in cancer. In 
this regard, a study using Y79 cells demonstrated that 
the expression of miR-34 was elevated after p53 
activation (40). Our results, consistent with previous 
studies, recommend that miR-34a-triggered cell 
apoptosis in response to the SD-208 might open a new 
window for better understanding and application of the 
kinase inhibitor-based therapy.  
Moreover, miR-20a was significantly downregulated 
in treated retinoblastoma cells with SD-208 compared to 
controls in this study. miR-20 belongs to the miR-17/92 
cluster and acts as an important oncogene in several 
cancers such as retinoblastoma (41) and targets genes 
important in regulating cell proliferation and cancer 
development. Previous studies have reported that this 
miRNA is involved in cellular proliferation (42) cell 
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cycle (43) and  invasion activity (41). As it mentioned, 
Y-79 cells do not functionally express TGFβRI, a key 
component for TGFβ signal transduction. Altogether, 
these observations postulate another alternative system 
by which miR-20a exerts its normal and abnormal 
biological function.  
The miR-17-92 cluster comprises six miRNAs: miR-
17, miR-18a, miR-19a, miR-19b, miR-20a , and miR-
92a (44). It has been well characterized that the miR-20a 
acts as an oncogene in various malignancies cells by 
targeting different cell signaling pathways (44-48). 
Evidence that the miRNA exhibits oncogenic effects in 
retinoblastoma came from distinct studies (49-53). Our 
results in agreement with these studies approved the 
miR-20a could potentially act as an oncogene in 
retinoblastoma. 
The most obvious reason to account for the 
mechanism(s) by which SD-208 could regulate the 
miRNAs in retinoblastoma could be due to different 
scenarios. Studies have reported the absence of TGFβRI 
in some cancerous cells such as Y-79 (54) and SW48 
cells (55). As mentioned before, SD-208 can block the 
biological effects of TGFβ cascades by inhibiting of the 
kinase activity of TGFβRI. In the present study also, we 
analyzed the TGFβRI and TGFβRII mRNA expression 
in the cells treated with and without the SD-208. We 
could not detect their mRNA in all tested samples (data 
not shown). Considering this phenomenon; it would be 
useful to explain an appropriate relationship between 
SD-208 and miRNA regulation under this circumstance. 
Our previous results showed that SD-208 could regulate 
miRNA-135b in colorectal cancer (55). Taken together, 
our findings support the notion that SD-208 could 
potentially regulate the miRNA expression by indirectly 
affecting the TGFβ signaling (also we called a non-
canonical pathway).  
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